Published in Mol Cancer Res on June 27, 2013
Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res (2016) 1.27
Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res (2013) 1.10
Chromatin regulation at the frontier of synthetic biology. Nat Rev Genet (2015) 1.01
Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity. Clin Epigenetics (2015) 0.99
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Engineered zinc-finger transcription factors activate OCT4 (POU5F1), SOX2, KLF4, c-MYC (MYC) and miR302/367. Nucleic Acids Res (2014) 0.87
Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics Chromatin (2015) 0.86
Epigenetic dysregulation by nickel through repressive chromatin domain disruption. Proc Natl Acad Sci U S A (2014) 0.84
Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res (2014) 0.81
Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Mol Oncol (2016) 0.81
Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat Commun (2016) 0.80
Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs. Epigenetics (2015) 0.80
Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. Mol Ther (2015) 0.79
Strategies for precision modulation of gene expression by epigenome editing: an overview. Epigenetics Chromatin (2015) 0.79
The epigenome: the next substrate for engineering. Genome Biol (2016) 0.77
CRISPR-Mediated Epigenome Editing. Yale J Biol Med (2016) 0.75
Epigenetic Editing: On the Verge of Reprogramming Gene Expression at Will. Curr Genet Med Rep (2016) 0.75
Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL. Leuk Lymphoma (2016) 0.75
dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res (2017) 0.75
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet (2010) 13.70
Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis (2003) 2.59
EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis (2010) 2.13
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Wnt signaling and Dupuytren's disease. N Engl J Med (2011) 2.02
Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics (2012) 1.65
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res (2010) 1.62
Nine patients with a microdeletion 15q11.2 between breakpoints 1 and 2 of the Prader-Willi critical region, possibly associated with behavioural disturbances. Eur J Med Genet (2009) 1.60
Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res (2012) 1.60
Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res (2003) 1.48
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res (2012) 1.40
Analysis of the differences in whole-genome expression related to asthma and obesity. Pol Arch Med Wewn (2015) 1.39
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol (2005) 1.32
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol (2008) 1.26
A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res (2009) 1.24
A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther (2004) 1.22
A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res (2006) 1.21
FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions. Am J Med Genet A (2006) 1.19
Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol (2012) 1.17
Effect of vemurafenib on a V600R melanoma brain metastasis. Eur J Cancer (2013) 1.13
Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther (2002) 1.11
PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol (2013) 1.10
Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res (2013) 1.10
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med (2012) 1.10
Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer (2009) 1.07
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06
MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol (2010) 1.05
Differentiation of induced pluripotent stem cells into functional oligodendrocytes. Glia (2011) 1.04
Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist (2011) 1.03
Genome-wide arrays: quality criteria and platforms to be used in routine diagnostics. Hum Mutat (2012) 1.03
CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes Cancer (2011) 0.99
BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma-derived cell line DEV. Hum Pathol (2006) 0.99
High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications. Hum Genet (2006) 0.98
Split hand/foot malformation due to chromosome 7q aberrations(SHFM1): additional support for functional haploinsufficiency as the causative mechanism. Eur J Hum Genet (2009) 0.97
Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer (2013) 0.97
Practical guidelines for interpreting copy number gains detected by high-resolution array in routine diagnostics. Eur J Hum Genet (2011) 0.96
Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. Genes Chromosomes Cancer (2005) 0.96
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol (2013) 0.95
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg (2014) 0.95
Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res (2006) 0.92
Systematic identification of tRNAome and its dynamics in Lactococcus lactis. Mol Microbiol (2014) 0.92
Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol (2009) 0.92
Local chromatin microenvironment determines DNMT activity: from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase. Epigenetics (2015) 0.91
A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology (2003) 0.91
18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl Med Commun (2006) 0.90
Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy. Am J Med Genet A (2003) 0.90
Engineering zinc finger protein transcription factors: the therapeutic relevance of switching endogenous gene expression on or off at command. J Mol Biol (2005) 0.90
Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol (2013) 0.90
Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol Carcinog (2007) 0.89
Targeted DNA methylation by a DNA methyltransferase coupled to a triple helix forming oligonucleotide to down-regulate the epithelial cell adhesion molecule. Bioconjug Chem (2010) 0.88
VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer (2011) 0.88
Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res (2004) 0.88
Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation. Int J Cancer (2008) 0.87
Selective targeting of adenovirus to alphavbeta3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. Int J Pharm (2010) 0.87
Copy number gain at 8q12.1-q22.1 is associated with a malignant tumor phenotype in salivary gland myoepitheliomas. Genes Chromosomes Cancer (2009) 0.86
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Ann Surg Oncol (2012) 0.86
The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney. Genes Chromosomes Cancer (2012) 0.86
PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Mol Pharm (2008) 0.85
Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res Ther (2006) 0.85
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Ann Surg Oncol (2013) 0.85
The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J Nucl Med (2005) 0.84
Copy number variants on the X chromosome in women with primary ovarian insufficiency. Fertil Steril (2011) 0.84
Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med (2004) 0.84
Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Mol Oncol (2013) 0.84
Upregulation of endogenous ICAM-1 reduces ovarian cancer cell growth in the absence of immune cells. Int J Cancer (2013) 0.84
Step out of the groove: epigenetic gene control systems and engineered transcription factors. Adv Genet (2006) 0.84
Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands. Cancer Epidemiol (2011) 0.84
Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematol Oncol (2007) 0.84
Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer (2010) 0.84
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist (2008) 0.83
Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther (2003) 0.83
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. J Nucl Med (2004) 0.83
Characteristics of dystonia in the 18p deletion syndrome, including a new case. Clin Neurol Neurosurg (2009) 0.83
Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound. Drug Deliv (2007) 0.83
Translocations involving 6p22 in acute myeloid leukaemia at relapse: breakpoint characterization using microarray-based comparative genomic hybridization. Br J Haematol (2004) 0.82
Endonucleases induced TRAIL-insensitive apoptosis in ovarian carcinoma cells. Exp Cell Res (2009) 0.82
Application of a comprehensive subtelomere array in clinical diagnosis of mental retardation. Eur J Med Genet (2005) 0.82
Effects of 5-fluorouracil adjuvant treatment of colon cancer. Expert Rev Anticancer Ther (2006) 0.81
A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology (2006) 0.81
Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. Acute Card Care (2006) 0.81
A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. Lung Cancer (2010) 0.81
Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res (2014) 0.81